Drug Profile
Research programme: antibodies - ImmunOs Therapeutics
Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator ImmunOs Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
- Research Autoimmune disorders
Most Recent Events
- 16 Apr 2024 Research programme: antibodies is still in early research development phase for Autoimmune disorder in Switzerland (ImmunOs Therapeutics Pipeline, April 2024)
- 16 Apr 2024 Preclinical trials in Haematological malignancies in Switzerland (Parenteral) (ImmunOs Therapeutics Pipeline, April 2024)
- 16 Apr 2024 Preclinical trials in Solid tumours in Switzerland (Parenteral) (ImmunOs Therapeutics Pipeline, April 2024)